FDA Orange Book
Generic for Univasc
Univasc contains moexipril. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Univasc is moexipril. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Univasc and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Univasc products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 15MG | Discontinued | None | 3 | AB |
| tablet, oral | 7.5MG | Discontinued | None | 3 | AB |
NDA 020312, held by UCB INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic moexipril
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| TEVA PHARMACEUTICALS USA INC | 076204 | AB (A-rated, therapeutically equivalent) | May 8, 2003 | 15MG, 7.5MG |
| CHARTWELL RX SCIENCES LLC | 077536 | AB (A-rated, therapeutically equivalent) | November 30, 2006 | 15MG, 7.5MG |
| GLENMARK PHARMACEUTICALS LTD | 090416 | AB (A-rated, therapeutically equivalent) | March 30, 2010 | 15MG, 7.5MG |
Questions
Is there a generic for Univasc?
Yes. The generic name for Univasc is moexipril. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Univasc?
The active ingredient in Univasc is moexipril, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.